Breast cancer is second most leading cause of death in all over the world and not only
limited to the females. Tamoxifen has been considered as the gold line therapy for estrogen
receptor positive breast cancer. However, this chemopreventive approach has been focused
at individuals in high risk group and limits its clinical applications to moderate and/or lower
risk groups. Moreover, Tamoxifen treatment is associated with a dose related hepatotoxicity
and nephrotoxicity and eventually results in poor quality of life of patients. Sulphoraphane, a …